Fred M. Powell

Fred M. Powell has over 20 years of global CFO experience in the biopharmaceutical industry, including investor relations, administration, operations and information technology. Most recently, Mr. Powell served as the executive vice president and chief financial officer of Antares Pharma, playing a strategic role in the successful $1.0 billion acquisition of Antares by Halozyme Therapeutics in May 2022. His prior CFO roles have been at companies including Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals), OraPharma, Inc. (acquired by Valeant Pharmaceuticals International) and BMP Sunstone Corporation (acquired by Sanofi-Aventis), and he also held various positions of increasing responsibility at KPMG LLP. Mr. Powell is the vice chairman of the Advisory Board for Penn State Scranton. He holds a B.S. in accounting from Pennsylvania State University.